Uncategorized Archives - Page 3 of 160

WednesdayJul 08, 2026 9:45 am

Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

Earth Science Tech acquires, operates, optimizes, and manages autonomous revenue-generating divisions across pharmaceuticals, telemedicine, retail, and real estate development This approach has created a “conglomerate” business model that separates ETST from other healthcare companies and enables the company to capture the profit margins at every step that other companies are forced to outsource ETST’s competitive advantages include its end-to-end vertical integration that covers all aspects of patient care (consultation, pharmacies, and fulfillment) as well as the provision of B2B tech and real estate This vertical integration has resulted in direct revenue growth while continually building the company’s product pipeline Earth…

TuesdayJul 07, 2026 10:00 am

Supreme Court Ruling Could Worsen the US Healthcare Crisis

There is general agreement that the healthcare system in the U.S. is in crisis, and a recent ruling issued by the Supreme Court could worsen the situation. This particular ruling allowed the federal government to end the TPS (temporary protected status) of noncitizens from particular countries, in this case Syria and Haiti. Under the TPS law that was passed back in 1990, the government, through Homeland Security, could grant temporary protected status to noncitizens from listed countries if those countries were deemed to be unsafe for their citizens in the U.S. to go back. The grounds for granting this status…

TuesdayJul 07, 2026 9:45 am

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

Knee osteoarthritis costs the U.S. healthcare system billions of dollars annually, creating growing demand for treatment options that can address cartilage damage before it progresses to more costly joint degeneration. Unlike complex cell-based therapies that often require multiple procedures and specialized laboratory processing, Gelrin C from Regentis is a cell-free, off-the-shelf hydrogel designed to fit within existing surgical workflows. With approximately 470,000 cartilage repair procedures performed annually in the U.S., Regentis is targeting a multi-billion-dollar market where providers, payers and patients are seeking more practical regenerative solutions. What begins as a localized cartilage defect can ultimately evolve into a significant…

WednesdayJul 01, 2026 10:40 am

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial capital to preclinical and early-stage innovation. The Jazz Pharmaceuticals–AbCellera collaboration illustrates how differentiated antibody technologies can command significant financial commitments before entering clinical development. VERAXA Biotech AG is positioning its technology platform across both ADCs and T-cell engagers, two therapeutic modalities that continue to attract strategic partnerships and acquisitions. Platform technologies and individual drug candidates both represent potential avenues for future partnering, licensing, and collaboration agreements. Recent transactions across the sector demonstrate that pharmaceutical companies are actively seeking access to…

WednesdayJul 01, 2026 10:30 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. MindBio kiosks use artificial intelligence and voice analysis to detect potential intoxication and fatigue in workplace environments. The company is targeting industries such as mining, aviation, construction, transportation, and law enforcement, where safety-sensitive operations require large-scale screening. MindBio’s AI models have been trained on more than 50 million data points and analyze over 140 acoustic markers associated with impairment. Prototype kiosks are entering testing, validation, and data-analysis phases, before broader commercial deployment. The company is positioning this important new technology as a faster and less invasive…

WednesdayJul 01, 2026 9:45 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. Quantum BioPharma executive co-chairman and co-founder Anthony Durkacz appeared as a guest on the BioMedWire Podcast. Durkacz outlined the company’s strategy for advancing Lucid-MS, the company’s lead drug candidate for multiple sclerosis. The Quantum BioPharma exec also provided an update on unbuzzd, the company’s innovative, clinically validated alcohol metabolism accelerator designed to help sober people up faster. Executive thought leadership has become an increasingly important component of corporate communications, particularly in highly specialized industries such as biotechnology. Through podcasts, interviews and other educational forums, company leaders…

TuesdayJun 30, 2026 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

Advances in digital health, cloud computing and data analytics are making it possible to move beyond episodic monitoring toward a more comprehensive understanding of cardiovascular health. HeartBeam’s proprietary HeartBeam System reflects the company’s mission to make cardiac monitoring accessible beyond the walls of a medical facility. The synthesized 12-lead ECG view provided by the system can help clinicians evaluate rhythm abnormalities and identify rhythm changes that may warrant additional investigation. Cardiac monitoring is evolving beyond the routine detection of abnormal heart rhythms toward a future where patients and physicians receive timely actionable insights that can guide clinical decisions outside of…

TuesdayJun 30, 2026 9:00 am

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Manufacturing and Development Efforts as It Pursues a Novel Approach to Hard-to-Treat Cancers

Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) and may include paid advertising. Onco-Innovations is advancing a new class of DNA Damage Response (“DDR”) therapies through the development of Polynucleotide Kinase Phosphatase (“PNKP”) inhibitors designed to disrupt cancer cells’ ability to repair DNA damage. The company recently achieved a key manufacturing milestone with the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010. A newly signed Letter of Intent with Nanosoft Polymers is expected to support polymer development, drug delivery optimization and formulation work for the ONC010 program. Cancers frequently exhibit defective repair of damaged…

MondayJun 29, 2026 10:30 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

Cardio Diagnostics has positioned the science of epigenetics at the center of its diagnostic platform. Looking at an individual person’s epigenetics can provide invaluable insight into the impact of their lifestyle, behavior, and environment. Epigenetics does more than pinpoint a problem, says CEO; it also provides some level of solution. When most people think about their risk for heart disease, they think about family history. Did a parent or grandparent have a heart attack? Is heart disease “in their genes”? It’s an understandable assumption, and genetics does play a role in cardiovascular risk. But a growing body of research suggests…

FridayJun 26, 2026 12:00 pm

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

For decades, cardiovascular risk assessment has centered on a checklist of factors never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling is that so much of this is preventable. Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics fields that examine how genes are expressed and regulated at the molecular level. Coronary heart disease (“CHD”) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume. Cardio Diagnostics Holdings (NASDAQ:…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Earth Science Tech Inc. (ETST) Is Building on Unique Competitive Advantages to Deliver Steady Growth

Supreme Court Ruling Could Worsen the US Healthcare Crisis

The $15 Billion Knee OA Spending Gap: Why Gelrin C Is the Smartest Investment in Cartilage Economics

Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) Delivers First Edge AI Intoxication Detection Kiosk Prototypes

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive Podcast

HeartBeam Inc. (NASDAQ: BEAT) Advances Modern Cardiac Care, Expanding Use of ECG Data Outside of the Hospital

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) Advances Manufacturing and Development Efforts as It Pursues a Novel Approach to Hard-to-Treat Cancers

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Leverages Epigenetics to Reveal Hidden Heart Disease Risks

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Brings Molecular Precision to a Blind Spot in Coronary Heart Disease (‘CHD’) Detection

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search